Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Curr Protoc ; 4(2): e995, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38406895

RESUMEN

Anesthesia and analgesia play pivotal roles in ethically and humanely using animal models in research, especially concerning mice and rats. These rodent species, extensively utilized in scientific investigations due to their genetic resemblance to humans, serve as invaluable tools for studying diseases and testing treatments. Proper anesthesia and analgesia not only prioritize animal welfare but also heighten experimental validity by minimizing stress-induced physiological responses. Recent years have seen remarkable advancements in anesthesia for mice and rats. The focus has shifted away from the 'one size fits all' toward tailoring anesthesia protocols, considering factors like age, strain, and the nature of the experimental procedure. The use of inhalation agents such as isoflurane and sevoflurane is often preferred due to their rapid induction and recovery characteristics, allowing precise control over anesthesia depth. However, refinements in injectable anesthetic agents also provide researchers the flexibility to select suitable agents based on study requirements. Additionally, progress in analgesic techniques has led to effective pain management strategies for these rodents. Common analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and local anesthetics are administered to alleviate pain and discomfort. However, standard practice also involves continuous monitoring of animals' behavior and physiological parameters, ensuring timely adjustments in analgesic regimens for optimal pain relief without compromising experimental outcomes. By integrating tailored anesthesia and analgesia protocols into the experimental design, researchers uphold high animal welfare standards while obtaining reliable scientific data. This contributes significantly to advancing medical knowledge and therapeutic interventions with reproducible results. Published 2024. This article is a U.S. Government work and is in the public domain in the USA. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Injectable anesthesia for mouse and rat Basic Protocol 2: Inhalant anesthesia using isoflurane for mouse and rat Basic Protocol 3: Analgesia for mice and rats.


Asunto(s)
Analgesia , Anestesia , Isoflurano , Humanos , Ratas , Ratones , Animales , Manejo del Dolor , Anestesia/métodos , Dolor , Analgésicos/farmacología , Analgésicos/uso terapéutico , Anestésicos Locales
3.
J Am Assoc Lab Anim Sci ; 56(1): 6-10, 2017 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-28905709

RESUMEN

Bacterial resistance to antimicrobial drugs has become a global health crisis. Physicians and veterinarians are embracing the concept of 'antimicrobial stewardship' (AMS) to preserve the efficacy of antibiotics for future generations. Antimicrobials are used in laboratory animals to treat clinical disease, to protect populations that may be vulnerable to infection, and in research projects including studies of the microbiome and to influence expression in genetically engineered animals. This overview provides a critical look at the use of antimicrobials in contemporary vivaria, with special attention to rodents because they are the most commonly used species in research and because antimicrobial use in rodents is not straightforward. Improvements in antibiotic use are encouraged with the goal of decreasing bacterial resistance while continuing to provide quality clinical care and research support. Suggestions are framed by using the 5 Rs: Reduce, Refine, Replace, and Review antimicrobial use in the vivarium, and take Responsibility for the judicious use of antibiotics in research animals.


Asunto(s)
Animales de Laboratorio , Antibacterianos/uso terapéutico , Programas de Optimización del Uso de los Antimicrobianos , Infecciones Bacterianas/veterinaria , Animales , Infecciones Bacterianas/prevención & control , Vivienda para Animales
4.
J Am Assoc Lab Anim Sci ; 51(1): 10-7, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22330862

RESUMEN

Physicians and veterinarians often prescribe oxytocin to treat dystocia. However, oxytocin administration to pregnant women or animals is not without risk. In the venue of laboratory animal medicine, the use of oxytocin may present confounding variables to research. Although oxytocin has been studied extensively, many of its physiologic effects and interactions with other hormones remain unclear. Investigator concerns about adverse and confounding effects of oxytocin in their research mice prompted the current review of oxytocin and its use to treat murine dystocia. Well-controlled studies of oxytocin in dystocic mice have not been conducted. However, in humans and other animals, inconsistent and adverse effects are well-documented. Limited knowledge of the complex physiologic and molecular mechanisms of action of oxytocin and scant support for the efficacy of oxytocin in dystocic mice fail to meet the standards of evidence-based veterinary medical practice. The administration of oxytocin is contraindicated in many cases of dystocia in research mice, and its use in dystocic mice may be unfounded. A brief review of oxytocin and the physiologic mechanisms of parturition are provided to support this conclusion. Alternative treatments for murine dystocia are discussed, and a holistic approach is advocated to better serve animal welfare and to safeguard the integrity of valuable research. Laboratory animal veterinarians overseeing the development of guidelines or standard operating procedures for technician or investigator treatment of dystocic mice should understand the effects of oxytocin administration in light of relevant research.


Asunto(s)
Animales de Laboratorio , Distocia/veterinaria , Oxitocina/efectos adversos , Oxitocina/uso terapéutico , Enfermedades de los Roedores/tratamiento farmacológico , Animales , Contraindicaciones , Árboles de Decisión , Distocia/tratamiento farmacológico , Medicina Basada en la Evidencia/métodos , Medicina Basada en la Evidencia/normas , Femenino , Ratones , Embarazo , Reproducción/efectos de los fármacos , Especificidad de la Especie
5.
Ann Neurol ; 64(4): 465-70, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18661558

RESUMEN

Early treatment with the histone deacetylase inhibitor, trichostatin A, plus nutritional support extended median survival of spinal muscular atrophy mice by 170%. Treated mice continued to gain weight, maintained stable motor function, and retained intact neuromuscular junctions long after trichostatin A was discontinued. In many cases, ultimate decline of mice appeared to result from vascular necrosis, raising the possibility that vascular dysfunction is part of the clinical spectrum of severe spinal muscular atrophy. Early spinal muscular atrophy disease detection and treatment initiation combined with aggressive ancillary care may be integral to the optimization of histone deacetylase inhibitor treatment in human patients.


Asunto(s)
Inhibidores Enzimáticos/uso terapéutico , Ácidos Hidroxámicos/uso terapéutico , Atrofia Muscular Espinal/terapia , Apoyo Nutricional/métodos , Factores de Edad , Animales , Animales Recién Nacidos , Peso Corporal/efectos de los fármacos , Peso Corporal/fisiología , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Ratones , Ratones Transgénicos , Actividad Motora/efectos de los fármacos , Necrosis , Análisis de Supervivencia , Proteína 1 para la Supervivencia de la Neurona Motora/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA